Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
1. A method for reversing anticoagulation in a subject undergoing an anticoagulant therapy with a factor Xa inhibitor, comprising administering to the subject from about 10 mg to about 2 grams of a two-chain polypeptide comprising a first chain comprising the amino acid sequence of SEQ ID NO:14 or a first polypeptide having at least 90% sequence identity to SEQ ID NO:14, and a second chain comprising the amino acid sequence of SEQ ID NO:15 or a second polypeptide having at least 95% sequence identity to SEQ ID NO:15, wherein the two-chain polypeptide has reduced catalytic activity as compared to the wild-type factor Xa protein, and is capable to bind to the factor Xa inhibitor.
2. The method of claim 1 , wherein about 100 mg to about 900 mg of the two-chain polypeptide is administered intravenously by bolus.
3. The method of claim 1 , wherein the two-chain polypeptide is administered as a combination of bolus plus infusion.
4. The method of claim 3 , wherein about 100 mg to about 900 mg of the two-chain polypeptide is administered as a bolus and the remaining is infused over a period until bleeding has substantially ceased.
5. The method of claim 3 , wherein the administration lasts up to about 6 hours.
6. The method of claim 1 , which comprises administering to the subject from about 100 mg to about 1.5 grams of the two-chain polypeptide.
7. The method of claim 1 , which comprises administering to the subject from about 200 mg to about 1 gram of the two-chain polypeptide.
8. The method of claim 1 , which comprises administering to the subject from about 400 mg to about 900 mg of the two-chain polypeptide.
9. The method of claim 1 , wherein the first chain comprises the amino acid sequence of SEQ ID NO:14 or a first polypeptide having at least 95% sequence identity to SEQ ID NO:14, and the second chain comprises the amino acid sequence of SEQ ID NO:15 or a second polypeptide having at least 95% sequence identity to SEQ ID NO:15.
10. The method of claim 9 , which comprises administering to the subject from about 100 mg to about 1.5 grams of the two-chain polypeptide.
11. The method of claim 9 , which comprises administering to the subject from about 200 mg to about 1 gram of the two-chain polypeptide.
12. The method of claim 9 , which comprises a bolus administration of about 200 mg to about 1 gram of the two-chain polypeptide.
13. The method of claim 1 , wherein the first chain comprises the amino acid sequence of SEQ ID NO:14, and the second chain comprises the amino acid sequence of SEQ ID NO:15.
14. The method of claim 13 , which comprises administering to the subject from about 100 mg to about 1.5 grams of the two-chain polypeptide.
15. The method of claim 13 , which comprises administering to the subject from about 200 mg to about 1 gram of the two-chain polypeptide.
16. The method of claim 1 , wherein the factor Xa inhibitor is selected from the group consisting of fondaparinux, idraparinux, biotinylated idraparinux, enoxaparin, fragmin, NAP-5, rNAPc2, tissue factor pathway inhibitor, DX-9065a, YM-60828, YM-150, apixaban, rivaroxaban, TAK-442, PD-348292, otamixaban, edoxaban, LY517717, GSK913893, razaxaban, low molecular weight heparin, betrixaban or a pharmaceutically acceptable salt thereof, and combinations thereof.
17. The method of claim 1 , wherein the factor Xa inhibitor is apixaban.
18. The method of claim 1 , wherein the factor Xa inhibitor is rivaroxaban.
19. The method of claim 1 , wherein the factor Xa inhibitor is edoxaban.
20. The method of claim 1 , wherein the factor Xa inhibitor is betrixaban.